Subtype | ||||
CDMS | RDMS | ECIS | SCIS | |
Further clinical events | Yes | No | No | No |
New MRI lesions | Not required | Yes | Yes | No |
Gender (F/M) | 42/12 | 6/10 | 8/5 | 15/7 |
Age at first event (years) (mean (SD)) | 33.0 (7.7) | 36.6 (6.3) | 34.3 (7.5) | 32.3 (7.5) |
T2 lesion volume (ml) (median (range)) | 1.3 (0.0–25.1) | 1.2 (0.3–9.6) | 0.1 (0.0–0.5) | 0.0 (0.0–0.8) |
T2 lesion number (median (range)) | 12 (0–142) | 13.5 (3–57) | 1 (0–6) | 0 (0–5) |
Gd enhancing lesion number (median (range)) | 0 (0–21) | 0 (0–13) | 0 (0–3) | 0 (0–0) |
First review EDSS (median (range)) | 1.0 (0.0–6.0) | 1.0 (0.0–3.0) | 1.0 (0.0–3.0) | 1.0 (0.0–4.0) |
6 year EDSS (median (range)) | 2.0 (0.0–7.5) | 1.0 (0.0–2.0) | 1.0 (0.0–2.0) | 1.0 (0.0–2.5) |
N=105, except for baseline EDSS, where N=103 (N=53 for CDMS and N=21 for SCIS) and 6-year EDSS scores, where N=104 (N=15 for RDMS).
CDMS, clinically definite multiple sclerosis; ECIS, evolving clinically isolated syndrome; EDSS, expanded disability status scale; RDMS, radiologically defined multiple sclerosis; SCIS, stable clinically isolated syndrome.